original ) (raw )Thrombocytopenia Secondary to Linezolid Administration: What Is the Risk?
Reuben Ramphal
Clinical Infectious Diseases, 2002
View PDFchevron_right
High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency
Yen-Hung Lin
International Journal of Antimicrobial Agents, 2006
View PDFchevron_right
Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination
Esra Kaya Kılıç
The Journal of Infection in Developing Countries
View PDFchevron_right
Population Pharmacokinetic and Pharmacodynamic Analysis of Linezolid and a Hematologic Side Effect, Thrombocytopenia, in Japanese Patients
Ahmed Suleiman
Antimicrobial Agents and Chemotherapy, 2011
View PDFchevron_right
Analysis of Linezolid-Associated Hematologic Toxicities in a Large Veterans Affairs Medical Center
Chris Gentry
Pharmacotherapy, 2010
View PDFchevron_right
Hematologic Effects of Linezolid: Summary of Clinical Experience
vu le
Antimicrobial Agents and Chemotherapy, 2002
View PDFchevron_right
Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers
Frédéric Frippiat
Antibiotics
View PDFchevron_right
Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study
Federico Pea
Journal of Antimicrobial Chemotherapy, 2019
View PDFchevron_right
Probable linezolid-induced pancytopenia
Nita Lakhani
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada, 2005
View PDFchevron_right
Association between serum linezolid concentration and haematological toxic effects: a longitudinal study
Shivalingappa Javali
International Surgery Journal, 2017
View PDFchevron_right
Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid
Alan Forrest
Antimicrobial Agents and Chemotherapy, 2014
View PDFchevron_right
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients
Piergiorgio Cojutti
Journal of Antimicrobial Chemotherapy, 2012
View PDFchevron_right
A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin
Antonio Rivera
Journal of Antimicrobial Chemotherapy, 2011
View PDFchevron_right
Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies
vu le
Antimicrobial Agents and Chemotherapy, 2003
View PDFchevron_right
Linezolid Does Not Increase the Risk of Thrombocytopenia in Patients with Nosocomial Pneumonia: Comparative Analysis of Linezolid and Vancomycin Use
vu le
Clinical Infectious Diseases, 2003
View PDFchevron_right
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
massimo baraldo
Basic & Clinical Pharmacology & Toxicology
View PDFchevron_right
Linezolid-induced haematological toxicity
Ana Ortega Eslava
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2015
View PDFchevron_right
Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid
Miguel Marcos
Antimicrobial Agents and Chemotherapy, 2007
View PDFchevron_right
Risk Factors for a Low Linezolid Trough Plasma Concentration in Acute Infections
Sebastian Rodriguez
Antimicrobial Agents and Chemotherapy, 2013
View PDFchevron_right